Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitors.

Autor: Wang X; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA., Li T; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA., Eljilany I; Departments of Cutaneous Oncology and Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA., Sukrithan V; Department of Internal Medicine, Ohio State University and Arthur G James Comprehensive Cancer Center, Columbus, OH 43210 USA., Ratan A; Center for Public Health Genomics, School of Medicine, University of Virginia, Charlottesville, VA 22903, USA., McCarter M; Department of Surgery, University of Colorado Cancer Center, Aurora, CO 80045, USA., Carpten J; City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA., Colman H; Department of Neurosurgery, School of Medicine, University of Utah, Salt Lake City, UT 84132, USA., Ikeguchi AP; University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Puzanov I; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA., Arnold S; Department of Medical Oncology, University of Kentucky Markey Cancer Center, Lexington, KY 40536, USA., Churchman M; Aster Insights, Hudson, FL 34667, USA., Hwu P; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA., Rodriguez PC; Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA., Dalton WS; Aster Insights, Hudson, FL 34667, USA., Weiner GJ; Department of Internal Medicine, Carver College of Medicine, University of Iowa Health Care, Iowa City, IA 52242, USA., Tarhini AA; Departments of Cutaneous Oncology and Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.

Publikováno v: MedRxiv : the preprint server for health sciences [medRxiv] 2024 Jul 21. Date of Electronic Publication: 2024 Jul 21.

A Bioinformatics Tool for Identifying Intratumoral Microbes from the ORIEN Dataset.

Autor: Wang C; Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, Ohio., Ma A; Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, Ohio.; Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio., Li Y; Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, Ohio., McNutt ME; Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, Ohio., Zhang S; Department of Human Sciences, College of Education and Human Ecology, The Ohio State University, Columbus, Ohio., Zhu J; Department of Human Sciences, College of Education and Human Ecology, The Ohio State University, Columbus, Ohio., Hoyd R; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio., Wheeler CE; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio., Robinson LA; Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Chan CHF; University of Iowa, Holden Comprehensive Cancer Center, Iowa City, Iowa., Zakharia Y; Division of Oncology, Hematology and Blood & Marrow Transplantation, University of Iowa, Holden Comprehensive Cancer Center, Iowa City, Iowa., Dodd RD; Department of Internal Medicine, University of Iowa, Iowa City, Iowa., Ulrich CM; Department of Population Health Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah., Hardikar S; Department of Population Health Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah., Churchman ML; Clinical & Life Sciences, M2GEN, Tampa, Florida., Tarhini AA; Departments of Cutaneous Oncology and Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Singer EA; Department of Urologic Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio., Ikeguchi AP; Department of Hematology/Oncology, Stephenson Cancer Center of University of Oklahoma, Oklahoma City, Oklahoma., McCarter MD; Department of Surgery, University of Colorado School of Medicine, Aurora, Colorado., Denko N; Department of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio., Tinoco G; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio., Husain M; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio., Jin N; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio., Osman AEG; Department of Internal Medicine, University of Utah, Salt Lake City, Utah., Eljilany I; Clinical Science Lab - Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Tan AC; Departments of Oncological Science and Biomedical Informatics, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah., Coleman SS; Departments of Oncological Science and Biomedical Informatics, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah., Denko L; Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio., Riedlinger G; Department of Precision Medicine, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey., Schneider BP; Indiana University Simon Comprehensive Cancer Center, Indianapolis, Indiana., Spakowicz D; Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio., Ma Q; Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, Ohio.; Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.

Publikováno v: Cancer research communications [Cancer Res Commun] 2024 Feb 05; Vol. 4 (2), pp. 293-302.

The tumor microbiome as a predictor of outcomes in patients with metastatic melanoma treated with immune checkpoint inhibitors.

Autor: Wheeler CE; Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Coleman SS 4th; Departments of Oncological Science and Biomedical Informatics, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Hoyd R; Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Denko L; Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.; Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Chan CHF; University of Iowa, Holden Comprehensive Cancer Center, Iowa City, IA, USA., Churchman ML; Clinical & Life Sciences, M2GEN, Tampa, FL, USA., Denko N; Department of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Dodd RD; Department of Internal Medicine, University of Iowa, Iowa City, IA, USA., Eljilany I; Clinical Science Lab -- Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Hardikar S; Department of Population Health Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Husain M; Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Ikeguchi AP; Department of Hematology/Oncology, Stephenson Cancer Center of University of Oklahoma, Oklahoma City, OK, USA., Jin N; Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Ma Q; Department of Biomedical Informatics, The Ohio State University, Columbus, OH, USA., McCarter MD; Department of Surgery, University of Colorado School of Medicine, Aurora, CO, USA., Osman AEG; Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA., Robinson LA; Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Singer EA; Department of Urologic Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Tinoco G; Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Ulrich CM; Department of Population Health Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Zakharia Y; Division of Oncology, Hematology and Blood & Marrow Transplantation, University of Iowa, Holden Comprehensive Cancer Center, Iowa City, IA, USA., Spakowicz D; Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.; Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Tarhini AA; Departments of Cutaneous Oncology and Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Tan AC; Departments of Oncological Science and Biomedical Informatics, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.

Publikováno v: BioRxiv : the preprint server for biology [bioRxiv] 2023 May 25. Date of Electronic Publication: 2023 May 25.

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF -Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.

Autor: Atkins MB; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC., Lee SJ; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Chmielowski B; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, Los Angeles, CA., Tarhini AA; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Cohen GI; Greater Baltimore Medical Center, Baltimore, MD., Truong TG; Kaiser Permanente Northern California, Vallejo, CA., Moon HH; Kaiser Permanente Southern California, Riverside, CA., Davar D; Hillman Cancer Center and University of Pittsburgh, Pittsburgh, PA., O'Rourke M; Greenville Health System Cancer Institute, Greenville, SC., Stephenson JJ; Greenville Health System Cancer Institute, Greenville, SC., Curti BD; Providence Cancer Institute, Portland, OR., Urba WJ; Providence Cancer Institute, Portland, OR., Brell JM; MetroHealth Cancer Center, Case Western Reserve University, Cleveland, OH., Funchain P; Cleveland Clinic Taussig Cancer Center, Cleveland, OH., Kendra KL; Ohio State University Comprehensive Cancer Center, Columbus, OH., Ikeguchi AP; University of Oklahoma Medical Center, Oklahoma City, OK., Jaslowski A; Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay, WI., Bane CL; Dayton Physicians LLC-Atrium, Dayton, OH., Taylor MA; Lewis Ca & Res Pavilion at Saint Joseph's/Candler, Savannah, GA., Bajaj M; Illinois CancerCare-P.C., Peoria, IL., Conry RM; University of Alabama at Birmingham, Birmingham, AL., Ellis RJ; CoxHealth South Hospital, Springfield, MO., Logan TF; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN., Laudi N; Mercy Hospital, St Louis Park, MN., Sosman JA; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL., Crockett DG; Nebraska Cancer Specialists, Grand Island, NE., Pecora AL; John Theurer Cancer Center, Hackensack, NJ., Okazaki IJ; Straub Medical Center-Kahului Clinic, Honolulu, HI., Reganti S; Renown Regional Medical Center, Reno, NV., Chandra S; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL., Guild S; AIM at Melanoma Foundation, Richmond, CA., Chen HX; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Streicher HZ; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Wolchok JD; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY., Ribas A; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, Los Angeles, CA., Kirkwood JM; Hillman Cancer Center and University of Pittsburgh, Pittsburgh, PA.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Jan 10; Vol. 41 (2), pp. 186-197. Date of Electronic Publication: 2022 Sep 27.